Literature DB >> 18042028

External validation of a nomogram for prediction of side-specific extracapsular extension at robotic radical prostatectomy.

Kevin C Zorn1, Andrea Gallina, Georg C Hutterer, Jochen Walz, Arieh L Shalhav, Gregory P Zagaja, Luc Valiquette, Ofer N Gofrit, Marcelo A Orvieto, Jerome B Taxy, Pierre I Karakiewicz.   

Abstract

BACKGROUND AND
PURPOSE: Several staging tools have been developed for open radical prostatectomy (ORP) patients. However, the validity of these tools has never been formally tested in patients treated with robot-assisted laparoscopic radical prostatectomy (RALP). We tested the accuracy of an ORP-derived nomogram in predicting the rate of extracapsular extension (ECE) in a large RALP cohort. PATIENTS AND METHODS: Serum prostate specific antigen (PSA) and side-specific clinical stage and biopsy Gleason sum information were used in a previously validated nomogram predicting side-specific ECE. The nomogram-derived predictions were compared with the observed rate of ECE, and the accuracy of the predictions was quantified. Each prostate lobe was analyzed independently. As complete data were available for 576 patients, the analyses targeted 1152 prostate lobes. Median age and serum PSA concentration at radical prostatectomy were 60 years and 5.4 ng/mL, respectively.
RESULTS: The majority of side-specific clinical stages were T(1c) (993; 86.2%). Most side-specific biopsy Gleason sums were 6 (572; 49.7%). The median side-specific percentages of positive cores and of cancer were, respectively, 20.0% and 5.0%. At final pathologic review, 107 patients (18.6%) had ECE, and side-specific ECE was present in 117 patients (20.3%). The nomogram was 89% accurate in the RALP cohort v 84% in the previously reported ORP validation.
CONCLUSIONS: The ORP side-specific ECE nomogram is highly accurate in the RALP population, suggesting that predictive and possibly prognostic tools developed in ORP patients may be equally accurate in their RALP counterparts.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18042028     DOI: 10.1089/end.2007.0044

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  5 in total

Review 1.  Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature.

Authors:  Giovanni Lughezzani; Alberto Briganti; Pierre I Karakiewicz; Michael W Kattan; Francesco Montorsi; Shahrokh F Shariat; Andrew J Vickers
Journal:  Eur Urol       Date:  2010-08-06       Impact factor: 20.096

2.  Novel predictive tools for Irish radical prostatectomy pathological outcomes: development and validation.

Authors:  D M Fanning; F Yue; J M Fitzpatrick; R W G Watson
Journal:  Ir J Med Sci       Date:  2009-07-14       Impact factor: 1.568

3.  External validation of a magnetic resonance imaging-based algorithm for prediction of side-specific extracapsular extension in prostate cancer.

Authors:  Piotr Zapała; Mieszko Kozikowski; Bartosz Dybowski; Łukasz Zapała; Jakub Dobruch; Piotr Radziszewski
Journal:  Cent European J Urol       Date:  2021-09-18

4.  International Multi-Site Initiative to Develop an MRI-Inclusive Nomogram for Side-Specific Prediction of Extraprostatic Extension of Prostate Cancer.

Authors:  Andreas G Wibmer; Michael W Kattan; Francesco Alessandrino; Alexander D J Baur; Lars Boesen; Felipe Boschini Franco; David Bonekamp; Riccardo Campa; Hannes Cash; Violeta Catalá; Sebastien Crouzet; Sounil Dinnoo; James Eastham; Fiona M Fennessy; Kamyar Ghabili; Markus Hohenfellner; Angelique W Levi; Xinge Ji; Vibeke Løgager; Daniel J Margolis; Paul C Moldovan; Valeria Panebianco; Tobias Penzkofer; Philippe Puech; Jan Philipp Radtke; Olivier Rouvière; Heinz-Peter Schlemmer; Preston C Sprenkle; Clare M Tempany; Joan C Vilanova; Jeffrey Weinreb; Hedvig Hricak; Amita Shukla-Dave
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

Review 5.  Postprostatectomy Erectile Dysfunction: A Review.

Authors:  Paolo Capogrosso; Andrea Salonia; Alberto Briganti; Francesco Montorsi
Journal:  World J Mens Health       Date:  2016-08-23       Impact factor: 5.400

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.